Lv1
24 积分 2025-07-02 加入
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
3天前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
3天前
已完结
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
10天前
已完结
Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis
12天前
已完结
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
13天前
已完结
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
13天前
已完结
Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis
16天前
已完结
Assessment of disease outcome measures in systemic sclerosis
16天前
已完结
Overview of Management and Outcome Assessment in Systemic Sclerosis
16天前
已关闭
Scleroderma From Pathogenesis to Comprehensive Management
16天前
已关闭
皖公网安备34019202002308
